# US 2016/0256573 A1 · Modified nucleic acids, and acute care uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256573 A1
- Document ID: US20160256573A1
- Status: Published application
- Kind: A1
- Application number: 15/130,064
- Filed: 2016-04-15
- Published: 2016-09-08
- Earliest claimed: 2011-12-14
- Assignees: Moderna Therapeutics, Inc.
- Applicants: Moderna Therapeutics, Inc.
- Inventors: Antonin de Fougerolles; Stephane Bancel
- Web page: https://patentgrep.com/patent/US20160256573A1

## CPC

- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 38/1891: {Angiogenesic factors; Angiogenin}
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides compositions and methods for effecting wound healing in a mammal, where the compositions include therapeutic mRNA which incorporate modified nucleosides and nucleotides.

## Claims

### Claim 1

A method of treating a mammalian subject in need thereof comprising administering an mRNA encoding a polypeptide of interest.

### Claim 2 (depends on 1)

The method of claim 1, wherein the mammalian subject is suffering from or is at risk of developing an acute or life-threatening disease or condition.

### Claim 3 (depends on 2)

The method of claim 2, wherein the mammalian subject is suffering from a traumatic injury.

### Claim 4 (depends on 2)

The method of claim 2, wherein the polypeptide of interest accelerates wound healing.

### Claim 5 (depends on 1)

The method of claim 1, wherein the mammalian subject is suffering from a bacterial infection and wherein the polypeptide of interest is an anti-microbial peptide (AMP).

### Claim 6 (depends on 5)

The method of claim 5, wherein the polypeptide of interest is an anti-viral.

### Claim 7 (depends on 1)

The method of claim 1, wherein the polypeptide of interest is a cytokine.

### Claim 8 (depends on 7)

The method of claim 7, wherein the mRNA is formulated and wherein the formulation is selected from the group consisting of lipid nanoparticle, polymer, hydrogel and surgical sealant.

### Claim 9 (depends on 8)

The method of claim 8, wherein the formulated mRNA is administered to the mammalian subject by a route selected from the group consisting of transdermal, epicutaneous, intradermal, subcutaneous, intravenous, intramuscular, transdermal, topical, and systemic.

### Claim 10 (depends on 9)

The method of claim 9, wherein the formulated mRNA is administered transdermally to the mammalian subject.

### Claim 11 (depends on 9)

The method of claim 9, wherein the formulated mRNA is administered topically to the mammalian subject.

### Claim 12 (depends on 8)

The method of claim 8, wherein the formulated mRNA is administered to the mammalian subject using bandages or dressings comprising the formulated mRNA.

### Claim 13 (depends on 1)

The method of claim 1, wherein the polypeptide of interest is a protein expressed by macrophages.

### Claim 14 (depends on 13)

The method of claim 13, wherein the mRNA is formulated and wherein the formulation is selected from the group consisting of lipid nanoparticle, polymer, hydrogel and surgical sealant.

### Claim 15 (depends on 14)

The method of claim 14, wherein the formulated mRNA is administered to the mammalian subject by a route selected from the group consisting of transdermal, epicutaneous, intradermal, subcutaneous, intravenous, intramuscular, transdermal, topical, and systemic.

### Claim 16 (depends on 14)

The method of claim 14, wherein the formulated mRNA is administered to the mammalian subject using bandages or dressings comprising the formulated mRNA.

### Claim 17 (depends on 1)

The method of claim 1, wherein the polypeptide of interest is an angiogenic growth factor.

### Claim 18 (depends on 17)

The method of claim 17, wherein the mRNA is formulated and wherein the formulation is selected from the group consisting of lipid nanoparticle, polymer, hydrogel and surgical sealant.

### Claim 19 (depends on 18)

The method of claim 18, wherein the formulated mRNA is administered to the mammalian subject by a route selected from the group consisting of transdermal, epicutaneous, intradermal, subcutaneous, intravenous, intramuscular, transdermal, topical, and systemic.

### Claim 20 (depends on 18)

The method of claim 18, wherein the formulated mRNA is administered to the mammalian subject using bandages or dressings comprising the formulated mRNA.
